Ryvu Therapeutics S.A. (WSE:RVU)

Poland flag Poland · Delayed Price · Currency is PLN
31.50
-0.90 (-2.78%)
Apr 24, 2025, 2:40 PM CET
-38.24%
Market Cap 749.09M
Revenue (ttm) 101.96M
Net Income (ttm) -111.44M
Shares Out 23.12M
EPS (ttm) -4.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,197
Average Volume 167,494
Open 32.60
Previous Close 32.40
Day's Range 31.15 - 33.00
52-Week Range 17.62 - 55.80
Beta 0.80
RSI 71.50
Earnings Date May 15, 2025

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 328
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RVU
Full Company Profile

Financial Performance

In 2024, Ryvu Therapeutics's revenue was 101.96 million, an increase of 51.51% compared to the previous year's 67.30 million. Losses were -111.44 million, 21.0% more than in 2023.

Financial Statements

News

There is no news available yet.